Pharmalittle: Early data suggests Gilead Covid-19 drug works; did FDA drop standards too far in hunt for chloroquine?

first_img Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. Tags pharmalittleSTAT+ By Ed Silverman April 17, 2020 Reprints Alex Hogan/STAT About the Author Reprints [email protected] Ed Silverman GET STARTED STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Pharmalot center_img What is it? What’s included? Log In | Learn More And so, another working week will soon draw to a close. Not a moment too soon, yes? After all, this has been another stressful and chaotic few days. Usually, we take this opportunity to daydream about weekend plans, but our agenda will be rather limited because we plan to work a wee bit more. That said, we do plan to promenade, when possible, with our new official mascot around the neighborhood. And what about you? This may be a good time to peek inside your pantry and take an inventory. You could tune out the world and read a book or binge-watch something on the telly. Or you could reach out to someone who is feeling especially isolated these days. Well, whatever you do, make the best of it. But be safe. See you soon.A Chicago hospital treating severe Covid-19 patients with remdesivir, the Gilead Sciences (GILD) antiviral, in a clinical trial is seeing rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week, STAT has learned. The trial recruited 125 people with Covid-19 into Gilead’s two Phase 3 clinical trials. Of those, 113 had severe disease. “The best news is that most of our patients have already been discharged, which is great. We’ve only had two patients perish,” said Kathleen Mullane of the University of Chicago. @Pharmalot Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED Pharmalittle: Early data suggests Gilead Covid-19 drug works; did FDA drop standards too far in hunt for chloroquine? last_img read more

Read More →